Sedation Propofol

RenJi Hospital · FDA-approved active Small molecule

Sedation Propofol is a Intravenous sedative-hypnotic Small molecule drug developed by RenJi Hospital. It is currently FDA-approved for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units. Also known as: EP.

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system.

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.

At a glance

Generic name	Sedation Propofol
Also known as	EP
Sponsor	RenJi Hospital
Drug class	Intravenous sedative-hypnotic
Target	GABA-A receptor
Modality	Small molecule
Therapeutic area	Anesthesia/Sedation
Phase	FDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization, which results in sedation and unconsciousness. It has a rapid onset (within seconds) and short duration of action due to rapid redistribution from the central nervous system to peripheral tissues and subsequent hepatic metabolism.

Approved indications

• Induction and maintenance of general anesthesia
• Sedation in mechanically ventilated patients in intensive care units

Common side effects

• Hypotension
• Respiratory depression
• Bradycardia
• Injection site pain
• Apnea
• Propofol infusion syndrome (with prolonged high-dose infusion)

Key clinical trials

• EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives (NA)
• Actualities in Procedural Sedation: Remimazolam (PHASE4)
• Target-controlled Infusion With Propofol in the Emergency Department : a Prospective Study on 45 Adult Patients (PHASE4)
• Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (PHASE3)
• Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1) (PHASE3)
• THRIVE in Sedated Gastrointestinal Endoscopy
• Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
• Characterizing Transcranial Focused Ultrasound Neuromodulation During Sedation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sedation Propofol CI brief — competitive landscape report
• Sedation Propofol updates RSS · CI watch RSS
• RenJi Hospital portfolio CI

Frequently asked questions about Sedation Propofol

What is Sedation Propofol?

Sedation Propofol is a Intravenous sedative-hypnotic drug developed by RenJi Hospital, indicated for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.

How does Sedation Propofol work?

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system.

What is Sedation Propofol used for?

Sedation Propofol is indicated for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.

Who makes Sedation Propofol?

Sedation Propofol is developed and marketed by RenJi Hospital (see full RenJi Hospital pipeline at /company/renji-hospital).

Is Sedation Propofol also known as anything else?

Sedation Propofol is also known as EP.

What drug class is Sedation Propofol in?

Sedation Propofol belongs to the Intravenous sedative-hypnotic class. See all Intravenous sedative-hypnotic drugs at /class/intravenous-sedative-hypnotic.

What development phase is Sedation Propofol in?

Sedation Propofol is FDA-approved (marketed).

What are the side effects of Sedation Propofol?

Common side effects of Sedation Propofol include Hypotension, Respiratory depression, Bradycardia, Injection site pain, Apnea, Propofol infusion syndrome (with prolonged high-dose infusion).

What does Sedation Propofol target?

Sedation Propofol targets GABA-A receptor and is a Intravenous sedative-hypnotic.

Related

• Drug class: All Intravenous sedative-hypnotic drugs
• Target: All drugs targeting GABA-A receptor
• Manufacturer: RenJi Hospital — full pipeline
• Therapeutic area: All drugs in Anesthesia/Sedation
• Indication: Drugs for Induction and maintenance of general anesthesia
• Indication: Drugs for Sedation in mechanically ventilated patients in intensive care units
• Also known as: EP